RxDoctor Payments Data

Anand Cholia, MD

Cardiovascular Disease · Midland, TXNPI 1881793461

Payments from drug & device makers

$1,364in general payments, 2019–2025

Across 68 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$501
  • Boston Scientific$274
  • Edwards Lifesciences$148
  • Medtronic$145
  • Novartis$75
  • AstraZeneca$60
  • plus $161 from 6 others

What the payments were for

  • Food & beverage$1,364100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,364 in reported general payments places this provider in the 25th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$565,583
Medicare patients
897
Services billed
5,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban477$362,419
XareltoRivaroxaban67$72,204
EntrestoSacubitril/Valsartan36$31,765
Metoprolol Succinate662$6,437
Nebivolol Hcl101$4,811
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide191$3,866
ClopidogrelClopidogrel Bisulfate429$3,848
Hydralazine Hcl161$2,608
Losartan Potassium330$2,600
Diltiazem 24hr Er (Cd)Diltiazem Hcl118$2,357
Atorvastatin Calcium260$2,021
Olmesartan Medoxomil182$1,855
Carvedilol331$1,784
Amiodarone Hcl118$1,707
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide207$1,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$75$31,76536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →